Mineralys Therapeutics (MLYS) Common Equity (2022 - 2026)

Mineralys Therapeutics (MLYS) has 5 years of Common Equity data on file, last reported at $638.1 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 86.83% year-over-year to $638.1 million; the trailing twelve-month figure through Mar 2026 stood at $638.1 million (up 86.83% YoY), and the FY2025 full-year result was $646.7 million, up 238.13% from the prior year.
• Common Equity retreated to $638.1 million in Q1 2026, from $646.7 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $646.7 million in Q4 2025 to a low of -$52.3 million in Q4 2022.
• A 5-year average of $263.9 million and a median of $285.0 million in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity soared 1070.88% in 2023 and declined 20.69% in 2024, its largest moves.
• Tracing MLYS's Common Equity over 5 years: stood at -$52.3 million in 2022, then surged by 561.37% to $241.2 million in 2023, then fell by 20.69% to $191.3 million in 2024, then surged by 238.13% to $646.7 million in 2025, then slipped by 1.32% to $638.1 million in 2026.
• Business Quant data shows MLYS's Common Equity at $638.1 million in Q1 2026, $646.7 million in Q4 2025, and $576.4 million in Q3 2025.